4th Jun 2021 06:16
(Alliance News) - AstraZeneca PLC on Thursday said drug lynparza reduced the risk of breast cancer recurrence by 42% in phase 3 trials.
The Cambridge, England-based pharmaceutical firm said that in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer, lynparza reduced the risk of recurrence by 42% in the OlympiA phase 3 trial.
BRCA refers to the breast cancer gene. A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes.
An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.
Lynparza also demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of distant disease-free survival in the overall trial population. Lynparza reduced the risk of distant disease recurrence or death by 43%.
"This is the first time that any medicine targeting a BRCA mutation has demonstrated the potential to change the course of early-stage breast cancer and offer hope for a cure. By providing a treatment which significantly reduces the risk of breast cancer returning in these high-risk patients, we hope Lynparza will set a new benchmark demonstrating sustained clinical benefit. We are working with regulatory authorities to bring Lynparza to these patients as quickly as possible," said Dave Fredrickson, executive vice president of the Oncology business unit.
Lynparza is being co-developed by AstraZeneca and New Jersey, US-based pharmaceutical drugs firm Merck & Co Inc.
OlympiA is a phase 3, double-blind, placebo-controlled, multicentre trial testing the efficacy and safety of lynparza tablets versus placebo as adjuvant treatment in patients with gBRCAm, high-risk, human epidermal growth factor receptor 2-negative early breast cancer, who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
By Greg Roxburgh; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca